Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
about
Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing?Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunitiesGranulomas and Inflammation: Host-Directed Therapies for Tuberculosis.Recent developments in the diagnosis and management of tuberculosis.New developments in anti-malarial target candidate and product profilesChronic physical conditions, multimorbidity and physical activity across 46 low- and middle-income countriesNew antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016).Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis.Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology.Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery.Toxoplasma gondii GRA7-Targeted ASC and PLD1 Promote Antibacterial Host Defense via PKCαSCMBYK: prediction and characterization of bacterial tyrosine-kinases based on propensity scores of dipeptides.The Discovery of 2-Aminobenzimidazoles That Sensitize Mycobacterium smegmatis and M. tuberculosis to β-Lactam Antibiotics in a Pattern Distinct from β-Lactamase Inhibitors.Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation.QSAR based therapeutic management of M. tuberculosis.A New Era in the Control of Tuberculosis.Evaluation of in vivo antimycobacterial activity of some folklore medicinal plants and enumeration of colony forming unit in murine model.BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcomeA Bioengineered Three-Dimensional Cell Culture Platform Integrated with Microfluidics To Address Antimicrobial Resistance in Tuberculosis.Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression.Proteogenomic Analysis and Discovery of Immune Antigens in Mycobacterium vaccae.Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.The paradigm shift to end tuberculosis. Are we ready to assume the changes?Interleukin-37: a new molecular target for host-directed therapy of tuberculosis.The long and winding road to inhaled TB therapy: not only the bug's fault.Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.Tuberculosis: Is the landscape changing?Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.Heightened circulating levels of antimicrobial peptides in tuberculosis-Diabetes co-morbidity and reversal upon treatment.Discovery of Indeno[1,2-c]quinoline Derivatives as Potent Dual Antituberculosis and Anti-Inflammatory Agents.ESRRA (estrogen-related receptor α) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense.Gene Expression Signatures in Tuberculosis Have Greater Overlap with Autoimmune Diseases Than with Infectious Diseases.Evaluation of the Mycobactericidal Effect of Thio-functionalized Carbohydrate Derivatives.Identification of the anti-mycobacterial functional properties of piperidinol derivatives.Abdominal tuberculosis: an old disease surprising young doctors.2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability.Tuberculosis case finding with combined rapid point of care assays (Xpert® MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique.Design, Synthesis and Characterization of N-oxide-containing Heterocycles with In vivo Sterilizing Antitubercular Activity.
P2860
Q26738321-24729D1A-069B-47CB-AEC7-8DB4CB04AB83Q28072376-0A1EE478-0EA3-48A1-B3F6-B334522368F7Q28076037-DAA4DF52-E681-465F-8AF7-428506402CF2Q28077124-B31A41D9-DA9C-4657-BA24-5D4AEC2A9CE8Q28468598-E32FE5E8-9EAE-4057-B9A9-81F489E01EC1Q29247960-E6CD638D-16F5-4F30-9252-DBE2953964D2Q30243915-6757146D-348F-4B88-A292-853F476D6E05Q30275004-D33994D9-1C21-4116-992C-60592E4A64DEQ30275673-5DD4B50E-2E0B-4BAD-9120-F837F8EA1CB4Q30402626-B17E001B-8536-4037-B5F9-E944C1C2AAEFQ33901126-44C748E8-23B1-4C85-9485-841D8A3B2F67Q36261479-9F77F287-FCB4-4EC4-846E-EBB6E8CE0AA3Q36268747-FE660857-5D0A-431D-A793-E0E0661016A9Q36293542-272C245D-73AA-4DB1-8CD5-E871871B235EQ36338646-80F586CD-B224-49AA-AC3F-9ED4CD85C28CQ36359056-508126AF-A27C-43A0-9188-02927149ED26Q37054033-9F14ED99-766D-4703-938F-B038C9F496A0Q37311970-7D08AF12-6264-43FD-A64A-E4C4B0EA2385Q37492943-06637DB5-05E4-4F48-A596-5DED19C63051Q37630254-03DA5830-5015-4A60-8118-AB6FB9B351E9Q37668063-D073E5B6-6D75-4209-AD4E-753FD19E5177Q38667238-59486369-EBBD-4223-ACB7-8A2BC2DFE1ABQ38674795-4AB18B91-4D32-4058-B569-9777A22FC84BQ38676708-13B7C948-C2CE-4B6E-8793-FDC887229D82Q38686666-AF07CBC6-7030-445B-8D83-160A073987B1Q38782463-6A02D833-75B4-4487-9FC1-05424625648BQ38929509-B31B91FD-12DE-4009-8AD9-7AB01516BE40Q38977113-CA59A145-126E-4A48-BE5E-BE7BE4E56C0CQ39354581-E8FDC8B7-C074-4EA5-B9A0-EA58DA14E36BQ39569711-F1F55711-AABC-496E-A29E-658EDF7BBDF9Q40046257-BE925A33-906A-4C1A-8FCB-332B95CC720FQ40052236-FE9C05CC-D16C-48DA-9B99-970BD33D2674Q40079643-4FA7D001-62B0-4932-8977-4080848A89F4Q40115642-485E2410-1969-4A34-82CE-925ADF9898DAQ40199657-7D01F8BB-C1DA-43FD-BB81-1AC0FB3065B4Q40333807-9248CA94-FC42-421F-A94D-110D2D6A34CFQ40468542-6AA32392-771F-4DAB-B3E7-171FBB91C398Q41293939-4BC3ED1F-481A-473F-A2F7-EE5C3E9F462CQ41922196-BB31CAEA-A57D-41C9-A8A1-437E3A00D67AQ41992338-C455D142-2A5B-46B7-8CEC-67A6CCE7D4CE
P2860
Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Tuberculosis--advances in deve ...... ted therapies, and biomarkers.
@en
type
label
Tuberculosis--advances in deve ...... ted therapies, and biomarkers.
@en
prefLabel
Tuberculosis--advances in deve ...... ted therapies, and biomarkers.
@en
P2093
P50
P1476
Tuberculosis--advances in deve ...... ted therapies, and biomarkers.
@en
P2093
Ben Marais
Gavin Churchyard
Jeremiah Chakaya
Marco Schito
Robert S Wallis
Roxana Rustomjee
P304
P356
10.1016/S1473-3099(16)00070-0
P50
P577
2016-04-01T00:00:00Z